Cargando…
The Dual Nature of Specific Immunological Activity of Tumor-derived gp96 Preparations
Mice immunized with optimal doses of autologous tumor–derived gp96 resist a challenge with the tumor that was the source of gp96. Immunization with quantities of gp96 5–10 times larger than the optimal dose does not elicit tumor immunity. This lack of effect is shown to be an active, antigen-specifi...
Autores principales: | Chandawarkar, Rajiv Y., Wagh, Mihir S., Srivastava, Pramod K. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
The Rockefeller University Press
1999
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2193068/ https://www.ncbi.nlm.nih.gov/pubmed/10224283 |
Ejemplares similares
-
GP96: safeguarding Treg
por: Zhang, Yongliang, et al.
Publicado: (2015) -
Gp96 Peptide Antagonist gp96-II Confers Therapeutic Effects in Murine Intestinal Inflammation
por: Nold-Petry, Claudia A., et al.
Publicado: (2017) -
Placenta-derived gp96 as a multivalent prophylactic cancer vaccine
por: Zhao, Bao, et al.
Publicado: (2013) -
Heat Shock Protein–Peptide Complexes, Reconstituted In Vitro, Elicit Peptide-specific Cytotoxic T Lymphocyte Response and Tumor Immunity
por: Blachere, Nathalie E., et al.
Publicado: (1997) -
Phase II Trial of Adjuvant Immunotherapy with Autologous Tumor-derived Gp96 Vaccination in Patients with Gastric Cancer
por: Zhang, Kecheng, et al.
Publicado: (2017)